Wegovy price in the UK: A complete guide

How much does Wegovy cost in the UK?

Private Wegovy prescriptions in the UK typically cost between £100 and £300 per month in 2026, depending on your dose and which provider you use. Lower doses at the start of treatment are cheaper; costs rise as you titrate upwards over the standard 16 to 20-week escalation schedule.

For most people, the full first year (working through titration to the standard 2.4 mg maintenance dose) will cost between £1,800 and £3,600 in medication alone, before any consultation fees, follow-up appointments, or additional services are factored in.

Those numbers are meaningful, and this guide is designed to help you understand exactly what you are paying for, where the variation comes from, and how to compare providers fairly.

Wegovy prices by dose: What to expect

Wegovy follows a gradual titration schedule, starting at 0.25 mg per week and increasing every four weeks up to the standard maintenance dose of 2.4 mg. A new higher dose of 7.2 mg was approved by the MHRA on 6 January 2026 for patients with a BMI of 30 or above who have reached and tolerated the 2.4 mg dose, though this is not available to all patients and is currently accessed primarily through private providers.

The table below shows typical private prescription retail prices across the UK market in 2026. Always confirm the current price, and exactly what is included, directly with your chosen provider before ordering.

Sources: GPhC-registered provider pricing, April 2026, as reported by Medino, Bolt Pharmacy, Totiva, and Slinic Pharmacy.

How much does Wegovy cost per month?

Understanding how monthly costs evolve over the course of treatment is important before you commit. Many people are surprised to find that what they pay in month one is not representative of what they will pay once they reach their maintenance dose.

A standard titration schedule looks like this:

• Months 1–2 (0.25–0.5 mg): Many providers charge the same for both starter doses, with prices starting from around £100 to £179 per month. These are the most affordable months of treatment.
• Months 3–4 (1–1.7 mg): Costs begin to rise as the dose increases, typically to £108–£220 per month.
• Month 5 onwards (2.4 mg): This is the standard maintenance dose and the most expensive stage for most patients, typically £169 to £289 per month depending on provider.

Based on current market pricing, a realistic first-year medication cost is approximately £1,800 to £3,600, with your highest monthly outgoing coming in the second half of the year once you are established at 2.4 mg.

Provider comparison: Major UK Wegovy suppliers

Price is only part of the picture when comparing providers. The level of clinical support included, the transparency of total pricing, and the model of care all vary considerably. The table below uses the 2.4 mg dose as a reference point, as this is the dose most patients will spend the longest time on.

Prices are approximate and based on provider data as of April 2026. Always confirm current pricing and exactly what is included before ordering.

What to look for beyond the headline price

Different providers bundle different things into their quoted cost. Before committing, confirm whether the following are included or charged separately: initial medical consultation and health assessment, delivery per order, repeat prescription fees, follow-up clinical appointments, blood tests if required, and sharps disposal.

Wegovy vs Mounjaro: Cost comparison

Before September 2025, Wegovy and Mounjaro were broadly comparable in price for most UK private patients. That changed when Eli Lilly increased Mounjaro's UK wholesale price by up to 170%, aligning it with other developed markets. Wegovy is now meaningfully cheaper at most dose stages, and the gap is significant over a full year of treatment.

Prices based on GPhC-registered UK provider data, April 2026.

At standard maintenance doses, Wegovy is typically £60 to £100 per month cheaper than Mounjaro, representing a difference of roughly £600 to £1,100 over a full year. For patients primarily focused on cost, this is a meaningful consideration.

The clinical picture is more nuanced. At standard doses, Mounjaro still produces greater average weight loss in head-to-head trials: 20.2% versus 13.7% in SURMOUNT-5 (New England Journal of Medicine, May 2025). However, the Wegovy 7.2 mg dose approved in January 2026 largely closes that gap, with average weight loss of 20.7% in the STEP UP trial. For patients who can access and tolerate the higher dose, the efficacy difference between the two treatments is now considerably smaller than it once was.

Ozempic vs Mounjaro vs Wegovy: Cost comparison

This is a commonly searched comparison that requires some important context before looking at prices.

Ozempic contains the same active ingredient as Wegovy (semaglutide) but is licensed for type 2 diabetes management, not weight loss. It is available on the NHS for patients who meet NICE criteria for diabetes treatment, and via private prescription. Current NHS guidance is clear that Ozempic should not be prescribed solely for weight loss, as this would displace supply for diabetes patients who need it. If you are looking for semaglutide for weight management, Wegovy is the appropriate licensed option.

Ozempic appears cheaper on a like-for-like basis, but it is not a legal or clinically appropriate route to semaglutide for weight loss. Any prescriber offering Ozempic off-label for weight management in the current supply environment is acting outside current NHS and professional guidance.

Where to buy Wegovy in the UK

Wegovy is a prescription-only medicine. It cannot legally be sold without a valid prescription from a UK-registered prescriber, and it cannot be purchased over the counter. Legitimate routes are as follows:

Online regulated clinics and pharmacies are the most common route for private patients. These services complete a medical assessment via an online questionnaire and a registered prescriber reviews your information before issuing a prescription. Services must be registered with the General Pharmaceutical Council (GPhC) and, for clinical services, the Care Quality Commission (CQC).

High-street pharmacies with online prescribing services, such as Boots Online Doctor, offer an alternative for patients who prefer the option of in-store collection alongside online assessment.

NHS specialist weight management services are the only route to Wegovy on the NHS for weight loss. 

Is there a cheaper Wegovy option? Generic semaglutide and compounded products

This is one of the most commonly asked questions about Wegovy cost, and the honest answer requires some clarity on the UK regulatory position.

There is no licensed generic Wegovy in the UK. Semaglutide 2.4 mg for weight management is currently only available as the branded Wegovy product manufactured by Novo Nordisk.

Compounded semaglutide, prepared by a pharmacy outside the branded manufacturing process, occupies a tightly regulated position in the UK. Compounding is legally permitted only in specific circumstances, such as when a licensed medicine is genuinely unavailable. It is not a legal route to a cheaper alternative when the licensed product is readily available through regulated channels.

The MHRA has warned publicly about the risks of unlicensed semaglutide products sold online and has conducted raids on illicit manufacturing facilities in the UK. Between January 2023 and October 2023, the MHRA seized 369 potentially fake Ozempic pens from online suppliers. Products obtained from unregulated sources may not contain the correct active ingredient, may be produced in non-sterile conditions, or may contain contaminants.

Wegovy discount codes and coupons

Some regulated providers do offer introductory pricing, referral codes, or reduced rates on multi-month supply. These can offer genuine savings and are worth factoring into your comparison. Introductory discounts for new patients are common at online providers and can reduce starter-dose costs meaningfully. Multi-month or subscription bundles sometimes offer a lower effective monthly rate than pay-per-order pricing, though they typically come with cancellation terms. Always read the cancellation policy before committing.

What discount codes cannot do is override the fundamental requirement to use a GPhC-registered, CQC-regulated provider. A discount from an unregulated service is a false economy: the potential risks to your health, and the cost of managing any complications, significantly outweigh any saving on the medication price.

Is Wegovy available on the NHS?

Yes, in principle, but access is more restricted in practice than many people expect.

NHS eligibility criteria

Wegovy was approved by NICE for use within specialist NHS weight management services under Technology Appraisal TA875, published in March 2023. To be eligible, patients must meet all of the following:

• A BMI of 35 or above, or 30–34.9 with at least one weight-related health condition such as type 2 diabetes, high blood pressure, sleep apnoea, or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, African, or African-Caribbean backgrounds, these thresholds are reduced by 2.5 kg/m².
• A referral to, and acceptance by, a specialist NHS weight management service (Tier 3 or Tier 4).
• Evidence of previous engagement with lifestyle interventions.
• No medical contraindications.

GPs cannot prescribe Wegovy directly on the NHS for weight loss. The prescribing decision sits with the specialist service, though your GP can refer you if you are likely to meet the criteria.

In April 2026, NHS England also published draft NICE guidance recommending that Wegovy be made available for adults with established cardiovascular disease and a BMI of 27 or above, to reduce the risk of heart attack and stroke. This represents a significant potential expansion of NHS eligibility and could ultimately reach over a million people in England. Final guidance is expected later in 2026.

The reality of NHS access in 2026

Even for eligible patients, the practical picture varies considerably by region. Specialist weight management services have long waiting lists in many areas (12 to 18 months or more in some regions), and some NHS trusts have implemented additional local criteria due to budget pressures. NICE guidance also limits NHS treatment to a maximum of two years, with a review at six months: if patients have not lost at least 5% of their starting body weight by that point, treatment is typically discontinued.

NHS prescription costs

NHS patients pay the standard prescription charge of £9.90 per item per month in England. Prescriptions are free in Scotland, Wales, and Northern Ireland for eligible patients, as well as for patients with certain medical exemptions or a pre-payment certificate.

Is Wegovy worth the cost?

This is ultimately a personal and clinical question, but the evidence base is strong enough to discuss objectively.

What the clinical trials show

The STEP clinical trial programme, published in the New England Journal of Medicine between 2021 and 2022, is the most comprehensive source of data on Wegovy's effectiveness. In STEP 1, a 68-week, placebo-controlled trial of 1,961 adults with obesity or overweight, participants on the 2.4 mg maintenance dose lost an average of 14.9% of their starting body weight, compared to 2.4% in the placebo group. Between 69 and 79% of participants achieved at least 10% weight loss, and 51 to 64% achieved 15% or more.

The STEP UP trial data, presented in November 2025 and supporting the January 2026 approval of the 7.2 mg dose, showed average weight loss of 20.7% over 72 weeks, broadly comparable to Mounjaro's results at the highest dose.

The broader health benefits

Weight loss of this magnitude carries measurable health benefits: improved blood pressure, lower HbA1c in people with type 2 diabetes, better cholesterol profiles, and reduced cardiovascular risk. The SELECT trial, which studied semaglutide in people with overweight or obesity and established cardiovascular disease, demonstrated a significant reduction in the risk of heart attack and stroke; this is the finding underpinning the new NHS draft guidance for this patient group.

What happens when you stop

The evidence also confirms something important about stopping treatment. The STEP 1 extension trial found that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within 52 weeks. This reflects the chronic nature of obesity as a condition, not a personal failure. It is, however, an important consideration for long-term budgeting and planning, and something worth discussing with your prescriber before you start.

The role of lifestyle alongside treatment

Patients who combine Wegovy with dietary changes, increased activity, and structured support consistently achieve better outcomes than those who rely on the medication alone. The treatment gives your biology a powerful assist; the habits you build around it are what make the difference in the long run.

Final thoughts

Wegovy is a clinically robust treatment with a meaningful evidence base behind it. For many patients, particularly those who have tried lifestyle changes alone and found them insufficient, the cost represents a genuine investment in health rather than a luxury.

Cost matters, though, and comparing providers properly on total price rather than headline figures is worth taking the time to do. Before committing, check GPhC registration, factor in every element of the quoted price, and ask your GP about NHS eligibility. It is also worth giving yourself a realistic picture of what treatment costs over a full year rather than just the first month.

Used correctly, with the right clinical support and realistic expectations, Wegovy is one of the most effective tools currently available for weight management in the UK.

FAQ